Compare AGYS & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGYS | VERA |
|---|---|---|
| Founded | 1963 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1B | 3.0B |
| IPO Year | 1994 | 2021 |
| Metric | AGYS | VERA |
|---|---|---|
| Price | $100.63 | $29.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | ★ $134.50 | $77.50 |
| AVG Volume (30 Days) | 181.0K | ★ 2.2M |
| Earning Date | 10-26-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 67.07 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $319,312,000.00 | N/A |
| Revenue This Year | $16.13 | N/A |
| Revenue Next Year | $16.93 | $792.38 |
| P/E Ratio | $313.47 | ★ N/A |
| Revenue Growth | ★ 15.85 | N/A |
| 52 Week Low | $61.50 | $23.05 |
| 52 Week High | $144.82 | $56.05 |
| Indicator | AGYS | VERA |
|---|---|---|
| Relative Strength Index (RSI) | 43.45 | 36.29 |
| Support Level | $94.74 | N/A |
| Resistance Level | $114.23 | $36.95 |
| Average True Range (ATR) | 3.60 | 2.09 |
| MACD | -0.16 | -0.41 |
| Stochastic Oscillator | 46.43 | 11.38 |
Agilysys Inc is engaged in hospitality software, delivering cloud-native SaaS and on-premise solutions for hotels, multi-amenity resorts, cruise lines, casinos, corporate foodservice management, restaurants, universities, stadiums, and healthcare facilities. The Company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. It operates across the Americas, Europe, the Middle East, Africa, Asia-Pacific, and India with headquarters located in Alpharetta, GA. The Company has one reportable segment serving the global hospitality industry.
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.